HeartBeam, Inc. (BEAT) - Q2 2024 10-Q Summary
Business Context and Reporting Period
HeartBeam, Inc. is a cardiac technology company developing higher resolution ambulatory Electrocardiogram (ECG) solutions using its proprietary Vector Electrocardiography (VECG) platform. The company is currently in the pre-revenue stage, seeking FDA clearance for its initial telehealth product, the HeartBeam AIMIGo. This report covers the quarterly period ended June 30, 2024.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Balance Sheet (June 30, 2024) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(4.96) million | $(9.56) million | N/A |
| Operating Expenses | $5.09 million | $9.87 million | N/A |
| Cash and Equivalents | N/A | N/A | $9.16 million |
| Operating Cash Flow | N/A | $(7.01) million | N/A |
| Debt | N/A | N/A | $0 (No long-term debt) |
| Stockholders' Equity | N/A | N/A | $8.71 million |
Note: Financial figures are in millions unless otherwise noted. The company reported no revenue for the periods presented.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the three months ended June 30, 2024, increased by 57% to $4.96 million compared to $3.15 million in the same period in 2023. The six-month loss increased by 31% to $9.56 million.
- R&D Expense Surge: Research and development expenses rose 92% quarter-over-quarter to $2.84 million, driven by increased headcount ($0.4 million), clinical and AI-related costs ($0.7 million), and consulting spend.
- Cash Position: Cash and cash equivalents decreased by approximately $7.0 million from $16.2 million at year-end 2023 to $9.2 million as of June 30, 2024, primarily due to operating losses.
- Financing Activity: The company raised minimal capital in the first half of 2024 ($0.08 million net proceeds from ATM sales) compared to $24.9 million in financing proceeds during the same period in 2023.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt regarding the company's ability to continue as a going concern. With a cash balance of $9.2 million, the company believes existing funds are insufficient to fund operations for the next twelve months.
- Capital Needs: Continued operations depend on raising additional capital through equity/debt financings or strategic relationships. The company has an At-The-Market (ATM) agreement allowing for the sale of up to $17 million of common stock, with approximately $16.9 million remaining available as of June 30, 2024.
- Regulatory Milestones: The company is in the substantive review phase with the FDA for its initial 3-lead device. It anticipates submitting a second 510(k) application for its 12-lead synthesis software in the second half of 2024. A limited launch of the 3-lead system is targeted for the end of 2024, though significant revenue is not expected until 12-lead clearance is obtained.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of June 30, 2024, citing material weaknesses including lack of proper approval processes and insufficient staff for segregation of duties.
- Revenue Expectations: Management expects no material commercial revenue in 2024.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $9.2 million cash balance against the stated burn rate and the timeline for FDA clearance.
- Financing Capability: Assess the likelihood of securing additional capital given the current market conditions and the company's reliance on the ATM facility.
- FDA Timeline: Monitor the status of the 510(k) submissions and the potential for delays in the "substantive review" phase.
- Internal Controls: Review the progress of remediation efforts regarding the material weaknesses in financial reporting controls.
- Expense Trajectory: Evaluate the sustainability of the 92% quarter-over-quarter increase in R&D expenses.